{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T02:46:11Z","timestamp":1789267571433,"version":"build-2803163510"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ctrv.2024.102697","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T11:41:54Z","timestamp":1707738114000},"page":"102697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Salivary gland carcinoma: Towards a more personalised approach"],"prefix":"10.1016","volume":"124","author":[{"given":"Layal","family":"Rached","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odile","family":"Casiraghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Even","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2024.102697_b0005","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12105-022-01420-1","article-title":"Update from the 5th edition of the World Health Organization classification of head and neck tumors: salivary glands","volume":"16","author":"Sk\u00e1lov\u00e1","year":"2022","journal-title":"Head Neck Pathol"},{"key":"10.1016\/j.ctrv.2024.102697_b0010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1615\/CritRevOncog.2018027598","article-title":"Current state of knowledge on salivary gland cancers","volume":"23","author":"Lin","year":"2018","journal-title":"Crit Rev Oncog"},{"key":"10.1016\/j.ctrv.2024.102697_b0015","unstructured":"What is salivary gland cancer | Salivary gland cancer | Cancer Research UK; n.d. https:\/\/www.cancerresearchuk.org\/about-cancer\/salivary-gland-cancer\/about (accessed October 2, 2022)."},{"key":"10.1016\/j.ctrv.2024.102697_b0020","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.oraloncology.2018.03.019","article-title":"Risk factors for salivary gland cancers in France: Results from a case-control study, the ICARE study","volume":"80","author":"Rado\u00ef","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0025","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jormas.2020.06.003","article-title":"Mucoepidermoid carcinoma. An update and review of the literature","volume":"121","author":"Peraza","year":"2020","journal-title":"J Stomatol Oral Maxillofac Surg"},{"key":"10.1016\/j.ctrv.2024.102697_b0030","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.suc.2021.12.008","article-title":"Management of malignant salivary gland conditions","volume":"102","author":"Pang","year":"2022","journal-title":"Surg Clin North Am"},{"key":"10.1016\/j.ctrv.2024.102697_b0035","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.580141","article-title":"Salivary gland carcinoma: novel targets to overcome treatment resistance in advanced disease","volume":"10","author":"Di Villeneuve","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0040","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3390\/cancers14051133","article-title":"Evaluation of the clinical utility of genomic profiling to inform selection of clinical trial therapy in salivary gland cancer","volume":"14","author":"Rack","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2024.102697_b0045","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1200\/JCO.2019.37.15_suppl.6001","article-title":"Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial","volume":"37","author":"Li","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0050","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.18.00545","article-title":"Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma","volume":"37","author":"Takahashi","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0055","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.annonc.2019.11.018","article-title":"Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study","volume":"31","author":"Kurzrock","year":"2020","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102069","article-title":"Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review","volume":"89","author":"Uijen","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2024.102697_b0065","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1097\/PAS.0000000000000980","article-title":"The role of molecular testing in the differential diagnosis of salivary gland carcinomas","volume":"42","author":"Sk\u00e1lov\u00e1","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2024.102697_b0070","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12105-017-0864-4","article-title":"Diagnostic approaches for salivary gland tumors with secretory and microcystic features","volume":"12","author":"Woo","year":"2018","journal-title":"Head Neck Pathol"},{"key":"10.1016\/j.ctrv.2024.102697_b0075","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.neo.2021.03.008","article-title":"SalvGlandDx \u2013 a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets","volume":"23","author":"Freiberger","year":"2021","journal-title":"Neoplasia"},{"key":"10.1016\/j.ctrv.2024.102697_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2022.02.002","article-title":"Comparison of gene fusion detection methods in salivary gland tumors","volume":"123","author":"Sun","year":"2022","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ctrv.2024.102697_b0085","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/PAS.0b013e3181d9efcc","article-title":"Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity","volume":"34","author":"Sk\u00e1lov\u00e1","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2024.102697_b0090","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.humpath.2020.11.017","article-title":"Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma","volume":"109","author":"Yamamoto","year":"2021","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ctrv.2024.102697_b0095","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0100","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102697_b0105","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors","volume":"28","author":"Demetri","year":"2022","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102697_b0110","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1200\/PO.19.00287","article-title":"Response and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of NTRK1","volume":"4","author":"Hemming","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0115","article-title":"Larotrectinib treatment for patients with TRK fusion-positive salivary gland cancers","author":"Le","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2024.102697_b0120","doi-asserted-by":"crossref","first-page":"viii23","DOI":"10.1093\/annonc\/mdz282","article-title":"TRK inhibitors in TRK fusion-positive cancers","volume":"30","author":"Drilon","year":"2019","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0125","doi-asserted-by":"crossref","first-page":"CT127","DOI":"10.1158\/1538-7445.AM2019-CT127","article-title":"Abstract CT127: Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi)","volume":"79","author":"Hyman","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102697_b0130","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","article-title":"Repotrectinib (TPX-0005) is a next-generation ROS1\/TRK\/ALK inhibitor that potently inhibits ROS1\/TRK\/ALK solvent \u2013 front mutations","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2024.102697_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.693394","article-title":"HER2 positivity in histological subtypes of salivary gland carcinoma: a systematic review and meta-analysis","volume":"11","author":"Egebjerg","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0140","first-page":"895","article-title":"ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing","volume":"35","author":"Ferguson","year":"2022","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"10.1016\/j.ctrv.2024.102697_b0145","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0150","first-page":"100273","article-title":"ERBB2 amplification and HER2 expression in salivary duct carcinoma: evaluation of scoring guidelines and potential for expanded anti-HER2 therapy","volume":"36","author":"McAfee","year":"2023","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"10.1016\/j.ctrv.2024.102697_b0155","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S1368-8375(03)00097-6","article-title":"Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study","volume":"39","author":"Haddad","year":"2003","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0160","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.2007.11.8612","article-title":"Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and\/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands","volume":"25","author":"Agulnik","year":"2007","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0165","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/annonc\/mdz291","article-title":"Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric\/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q","volume":"30","author":"Jhaveri","year":"2019","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105703","article-title":"Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma","volume":"125","author":"Uijen","year":"2022","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0175","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1200\/JCO.2021.39.15_suppl.6079","article-title":"Trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing salivary duct carcinoma: Subgroup analysis of two phase 1 studies","volume":"39","author":"Bando","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0180","article-title":"Targeting HER2\/neu oncogene overexpression with ado-trastuzumab emtansine in the treatment of metastatic salivary gland neoplasms: A single-institution experience","volume":"3","author":"Swed","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0185","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1158\/2159-8290.CD-19-1014","article-title":"Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors","volume":"10","author":"Tsurutani","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2024.102697_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2022.105905","article-title":"Anti-PD-1 plus anti-HER2 and chemotherapy showed superior and durable clinical benefit in a patient with advanced salivary duct carcinoma","volume":"130","author":"Ma","year":"2022","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0195","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/jso.24266","article-title":"Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas","volume":"114","author":"Mukaigawa","year":"2016","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0200","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/COC.0000000000000429","article-title":"Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE-028 study","volume":"41","author":"Cohen","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0205","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1634\/theoncologist.2012-0369","article-title":"Trastuzumab for the treatment of salivary duct carcinoma","volume":"18","author":"Limaye","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2024.102697_b0210","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1634\/theoncologist.2019-0841","article-title":"The benefits of adjuvant trastuzumab for HER-2-positive salivary gland cancers","volume":"25","author":"Hanna","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2024.102697_b0215","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1309\/RVTP1G0Q727WJUQD","article-title":"Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors. Frequent expression of androgen receptor in a subset of malignant salivary gland tumors","volume":"119","author":"Nasser","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ctrv.2024.102697_b0220","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdx771","article-title":"A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma","volume":"29","author":"Fushimi","year":"2018","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0225","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3389\/fonc.2019.00701","article-title":"First line androgen deprivation therapy vs. chemotherapy for patients with androgen receptor positive recurrent or metastatic salivary gland carcinoma-a retrospective study","volume":"9","author":"Viscuse","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0230","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.00229","article-title":"Phase II study of enzalutamide for patients with androgen receptor-positive salivary gland cancers (Alliance A091404)","author":"Ho","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0235","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1200\/JCO.21.00468","article-title":"Abiraterone acetate in patients with castration-resistant, androgen receptor-expressing salivary gland cancer: A phase II trial","volume":"39","author":"Locati","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"110","key":"10.1016\/j.ctrv.2024.102697_b0240","first-page":"62","article-title":"Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma","volume":"2019","author":"van Boxtel","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.ctrv.2024.102697_b0245","first-page":"1598","article-title":"Tailoring treatment of salivary duct carcinoma (SDC) by liquid biopsy: ARv7 expression in circulating tumor cells","volume":"29","author":"Cappelletti","year":"2018","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0250","article-title":"The role of the EZH2 and H3K27me3 expression as a predictor of clinical outcomes in salivary duct carcinoma patients: a large-series study with emphasis on the relevance to the combined androgen blockade and HER2-targeted therapy","volume":"11","author":"Saigusa","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0255","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.3390\/cancers13143527","article-title":"Predictive and prognostic biomarker identification in a large cohort of androgen receptor-positive salivary duct carcinoma patients scheduled for combined androgen blockade","volume":"13","author":"Lassche","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2024.102697_b0260","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","article-title":"A comprehensive survey of Ras mutations in cancer","volume":"72","author":"Prior","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102697_b0265","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1093\/annonc\/mdu143","article-title":"The mutational spectrum of squamous-cell carcinoma of the head and neck: targetable genetic events and clinical impact","volume":"25","author":"Mountzios","year":"2014","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0270","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1093\/annonc\/mdx399","article-title":"Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies","volume":"28","author":"Ross","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0275","doi-asserted-by":"crossref","first-page":"25631","DOI":"10.18632\/oncotarget.4554","article-title":"Genomic landscape of salivary gland tumors","volume":"6","author":"Kato","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2024.102697_b0280","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1200\/JCO.20.02903","article-title":"Tipifarnib in head and neck squamous cell carcinoma with HRAS mutations","volume":"39","author":"Ho","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0285","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1002\/cncr.33036","article-title":"Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer","volume":"126","author":"Hanna","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2024.102697_b0290","article-title":"Notch signaling pathway","volume":"2006","author":"Ehebauer","year":"2006","journal-title":"Sci STKE Signal Transduct Knowl Environ"},{"key":"10.1016\/j.ctrv.2024.102697_b0295","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/annonc\/mdy171","article-title":"A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors","volume":"29","author":"Ferrarotto","year":"2018","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0300","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s10637-019-00739-x","article-title":"Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma","volume":"38","author":"Even","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ctrv.2024.102697_b0305","doi-asserted-by":"crossref","first-page":"6046","DOI":"10.1200\/JCO.2022.40.16_suppl.6046","article-title":"Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent\/metastatic (R\/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut)","volume":"40","author":"Ferrarotto","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0310","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1517\/14728222.2011.645805","article-title":"Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy","volume":"16","author":"Santarpia","year":"2012","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.ctrv.2024.102697_b0315","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.6004\/jnccn.2018.7056","article-title":"First-line treatment of widely metastatic BRAF-mutated salivary duct carcinoma with combined BRAF and MEK inhibition","volume":"16","author":"Lin","year":"2018","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"10.1016\/j.ctrv.2024.102697_b0320","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1186\/2193-1801-2-679","article-title":"Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment","volume":"2","author":"Boyrie","year":"2013","journal-title":"Springerplus"},{"key":"10.1016\/j.ctrv.2024.102697_b0325","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102697_b0330","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1101\/gad.13.22.2905","article-title":"Cellular survival: a play in three Akts","volume":"13","author":"Datta","year":"1999","journal-title":"Genes Dev"},{"key":"10.1016\/j.ctrv.2024.102697_b0335","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fonc.2014.00064","article-title":"Targeting PI3K\/Akt\/mTOR signaling in cancer","volume":"4","author":"Porta","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0340","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1158\/1535-7163.MCT-10-0994","article-title":"PIK3CA mutations in patients with advanced cancers treated with PI3K\/AKT\/mTOR axis inhibitors","volume":"10","author":"Janku","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2024.102697_b0345","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1073\/pnas.0510857103","article-title":"Cancer-specific mutations in PIK3CA are oncogenic in vivo","volume":"103","author":"Bader","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ctrv.2024.102697_b0350","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1002\/cncr.31600","article-title":"Frequent PTEN loss and differential HER2\/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy","volume":"124","author":"Saintigny","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2024.102697_b0355","article-title":"Excellent response with alpelisib and bicalutamide for advanced salivary duct carcinoma with PIK3CA mutation and high androgen receptor expression-a case report","volume":"18","author":"Sheth","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0360","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41419-021-03391-7","article-title":"Survival of salivary gland cancer stem cells requires mTOR signaling","volume":"12","author":"Andrade","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ctrv.2024.102697_b0365","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.prp.2014.03.008","article-title":"Temsirolimus, the mTOR inhibitor, induces autophagy in adenoid cystic carcinoma: in vitro and in vivo","volume":"210","author":"Liu","year":"2014","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.ctrv.2024.102697_b0370","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.oraloncology.2012.05.005","article-title":"Epidermal growth factor receptor (EGFR) in salivary gland carcinomas: potentials as therapeutic target","volume":"48","author":"Clauditz","year":"2012","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0375","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.oraloncology.2008.07.010","article-title":"Cetuximab in recurrent and\/or metastatic salivary gland carcinomas: A phase II study","volume":"45","author":"Locati","year":"2009","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0380","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3892\/mco.2017.1226","article-title":"Salivary duct carcinoma treated with cetuximab-based targeted therapy: A case report","volume":"6","author":"Kawahara","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0385","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hed.23647","article-title":"Phase II study of gefitinib in patients with advanced salivary gland cancers","volume":"37","author":"Jakob","year":"2015","journal-title":"Head Neck"},{"key":"10.1016\/j.ctrv.2024.102697_b0390","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1158\/1078-0432.CCR-10-0463","article-title":"Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinicopathologic significance","volume":"16","author":"Mitani","year":"2010","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102697_b0395","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1084\/jem.20180939","article-title":"Zebrafish blastomere screen identifies retinoic acid suppression of MYB in adenoid cystic carcinoma","volume":"215","author":"Mandelbaum","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.ctrv.2024.102697_b0400","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx017","article-title":"Targeting the oncogenic transcriptional regulator MYB in adenoid cystic carcinoma by inhibition of IGF1R\/AKT signaling","volume":"109","author":"Andersson","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2024.102697_b0405","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1200\/JCO.2011.36.9678","article-title":"Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft","volume":"30","author":"Morelli","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0410","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1158\/1078-0432.CCR-15-2301","article-title":"A phase I clinical trial and independent patient-derived xenograft study of combined targeted treatment with dacomitinib and figitumumab in advanced solid tumors","volume":"23","author":"Calvo","year":"2017","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102697_b0415","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41389-020-0194-3","article-title":"ATR is a MYB regulated gene and potential therapeutic target in adenoid cystic carcinoma","volume":"9","author":"Andersson","year":"2020","journal-title":"Oncogenesis"},{"key":"10.1016\/j.ctrv.2024.102697_b0420","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.oraloncology.2008.03.012","article-title":"t(11;19) translocation and CRTC1-MAML2 fusion oncogene in mucoepidermoid carcinoma","volume":"45","author":"O\u2019Neill","year":"2009","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0425","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/ng1083","article-title":"t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway","volume":"33","author":"Tonon","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2024.102697_b0430","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139497","article-title":"The CRTC1-MAML2 fusion is the major oncogenic driver in mucoepidermoid carcinoma","volume":"6","author":"Chen","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.ctrv.2024.102697_b0435","doi-asserted-by":"crossref","first-page":"16988","DOI":"10.1038\/s41598-020-73965-6","article-title":"Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma","volume":"10","author":"Niwa","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2024.102697_b0440","article-title":"NISCAHN: a phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08)","volume":"2","author":"Fayette","year":"2023","journal-title":"BMJ Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0445","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1038\/s41591-023-02518-x","article-title":"Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial","volume":"29","author":"Vos","year":"2023","journal-title":"Nat Med"},{"issue":"171","key":"10.1016\/j.ctrv.2024.102697_b0450","first-page":"259","article-title":"Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study","volume":"2022","author":"Even","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.ctrv.2024.102697_b0455","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijrobp.2020.08.018","article-title":"A randomized phase 2 study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma","volume":"109","author":"Mahmood","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2024.102697_b0460","doi-asserted-by":"crossref","first-page":"6048","DOI":"10.1200\/JCO.2023.41.16_suppl.6048","article-title":"A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent\/metastatic adenoid cystic carcinoma","volume":"41","author":"Mohamadpour","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0465","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1200\/JCO.22.02221","article-title":"Phase II clinical trial of axitinib and avelumab in patients with recurrent\/metastatic adenoid cystic carcinoma","volume":"41","author":"Ferrarotto","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102697_b0470","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.21.00449","article-title":"Management of salivary gland malignancy: ASCO guideline","volume":"39","author":"Geiger","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722400015X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722400015X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:31:45Z","timestamp":1759656705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573722400015X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":94,"alternative-id":["S030573722400015X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102697","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Salivary gland carcinoma: Towards a more personalised approach","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102697","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102697"}}